Tuberculosis preventive treatment delivered real-world clinical gains and lowered mortality among people with HIV across six high-burden countries, according to a prospective cohort study published in The Lancet HIV. Researchers from the Centers for Disease Control and Prevention and Emory University found the intervention works effectively in routine public health programs.
Tuberculosis has remained one of the most consequential threats in global HIV care. While clinical trials established that preventive medicines can stop latent infections from flaring into active disease, public health leaders faced a persistent implementation gap. Routine clinics often struggled to deliver prophylactic regimens smoothly across complex health systems. A new study published in The Lancet HIV now confirms that these preventive measures yield substantial, measurable protections when deployed at scale in ordinary clinical settings.
Real-World Data From Six High-Burden Nations
The investigation combined a prospective cohort study with a meta-analysis to evaluate outcomes in Haiti, Kenya, Nigeria, Uganda, Ukraine, and Zimbabwe. These nations carry substantial burdens of both HIV and tuberculosis, making them rigorous test environments for ordinary public health delivery. Rather than relying on the tightly managed parameters of a conventional clinical trial, the research team examined routine health-program data.
Tuberculosis is responsible for about a quarter of all AIDS-related deaths and remained the leading cause of death among people with HIV in 2024. The underlying biology explains why the two conditions collide so aggressively. When Mycobacterium tuberculosis enters the body through the air, the immune system frequently traps the bacteria inside cellular structures called granulomas. This dormant state can persist for years without symptoms. However, as HIV depletes populations of CD4 T cells and weakens immune surveillance, the contained bacteria can multiply and spread beyond the lungs.
“What is powerful about these findings is that they come from routine HIV programs, not from a controlled clinical trial,” said Anand Date, chief of CDC’s Global TB Branch. “This is program data showing what happens when countries deliver TB preventive treatment at scale.”
Anand Date, chief of CDC’s Global TB Branch
The Protective Mechanism of Isoniazid and Timing
Most participants in the evaluation received six months of isoniazid, a medication that disrupts the production of mycolic acids essential to the cell wall of the tuberculosis bacterium. By suppressing dormant bacteria, the drug halts the progression from latent infection to active disease. The analysis showed that this protective effect held firm across a wide variety of national settings, health conditions, and patient risk groups.
Timing emerged as a vital operational factor. Researchers observed that preventive treatment delivered the strongest benefit when initiated early in a patient’s HIV care journey. Ideally, clinicians should start the regimen within the first two weeks after a person enters an HIV program, though treatments begun within eight weeks still provided meaningful health benefits. Initiating prophylaxis during this critical window helps clear latent infections before compromised immune systems allow them to advance unchecked.
Antiretroviral therapy suppresses viral replication and supports partial immune recovery, but it does not eradicate tuberculosis bacteria already present in the body. Preventive treatment addresses that distinct biological risk.
Funding Pressures and Sustaining Global Health Gains
The findings arrive at a precarious moment for international public health initiatives. Global HIV and tuberculosis prevention efforts have encountered severe disruptions following freezes on foreign aid, the dissolution of USAID, and reductions in PEPFAR funding. Analysts project that cutting resources for tuberculosis programs could lead to more than half a million additional deaths from the disease alongside catastrophic financial costs for affected families.
“Taken together, the findings support the critical role of tuberculosis preventive treatment in HIV care programs,” says Sarita Shah, MD, MPH, professor of epidemiology and global health at Rollins. “This is important in the current context of reduced funding for global health programs to ensure that gains made in HIV care over the last two decades are sustained.”
Sarita Shah, MD, MPH, professor of epidemiology and global health at Rollins
Since a major commitment by the U.S. President’s Emergency Plan for AIDS Relief in 2018, more than 13 million people living with HIV worldwide have received tuberculosis preventive treatment. Integrating TB screening, rapid linkage to care, antiretroviral therapy, and viral-load monitoring into a unified clinical architecture remains essential to preserving those gains as funding streams face renewed uncertainty.
